Unified neurobiomarker Cognition's COGNISION360 platform consolidates EEG, ERP, PSG, eye tracking, wearables, and digital clinical outcomes, presenting a turnkey opportunity to offer a comprehensive neurocognitive biomarker solution to CNS drug developers and clinical trial sponsors.

FDA-cleared edge The COGNISION system is FDA-cleared and cloud-powered, enabling scalable deployment in multi-site trials and offering risk mitigation for sponsors seeking compliant, reliable neurocognitive assessment tooling.

Clinical trial traction The system has already been implemented in multiple CNS trials, suggesting a proven value proposition for customers pursuing precision EEG/ERP biomarkers in CNS drug development and an easy pathway for expanded adoption.

Strategic partnerships As a founding member of the EEG/ERP Biomarker Qualification Consortium, Cognision can leverage collaborative credibility and potential co-development opportunities to accelerate qualification timelines and access targeted sponsor networks.

Growth-ready scale With a focused domain, cloud-based platform, and mid-market revenue scale, Cognision presents a clear up-sell and cross-sell opportunity to adjacent neurotechnology firms and CROs seeking integrated biomarker infrastructure and data integration capabilities.